AnaptysBio, Inc. (ANAB)

Market Cap	531.78M
Revenue (ttm)	17.16M
Net Income (ttm)	-163.62M
Shares Out	26.76M
EPS (ttm)	-6.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	281,568
Open	19.61
Previous Close	19.83
Day's Range	19.08 - 20.66
52-Week Range	13.36 - 27.50
Beta	-0.29
Analysts	Buy
Price Target	46.22 (+132.61%)
Earnings Date	May 9, 2024

About ANAB

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and I...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 26, 2017
• Employees: 117
• Stock Exchange: NASDAQ
• Ticker Symbol: ANAB

Financial Performance

In 2023, AnaptysBio's revenue was $17.16 million, an increase of 66.78% compared to the previous year's $10.29 million. Losses were -$163.62 million, 27.1% more than in 2022.

Analyst Forecast

According to 9 analysts, the average rating for ANAB stock is "Buy." The 12-month stock price forecast is $46.22, which is an increase of 132.61% from the latest price.

Price Target

$46.22

(132.61% upside)

Analyst Consensus: Buy